4269-94-7

Basic information

• Product Name: 6-Iodouracil
• Synonyms: 2,4(1H,3H)-Pyrimidinedione, 6-iodo-;6-iodo-1,2,3,4-tetrahydropyriMidine-2,4-dione;6-iodouracil:6-iodo-1h-pyrimidine-2,4-dione;6-IODOURACIL;6-Iodo-1H-pyrimidine-2,4-dione
• CAS NO: 4269-94-7
• Molecular Formula: C₄H₃IN₂O₂
• Molecular Weight: 237.98
• Mol File: 4269-94-7.mol

Chemical Properties

• Appearance: /
• Density: 2.394 g/cm³
• Refractive Index: 1.705
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 6.32±0.10(Predicted)
• CAS DataBase Reference: 6-Iodouracil(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Iodouracil(4269-94-7)
• EPA Substance Registry System: 6-Iodouracil(4269-94-7)

Safety Data

• Hazardous Substances Data: 4269-94-7(Hazardous Substances Data)

Usage

Uses

Used in Molecular Biology and Biochemistry Research:
6-Iodouracil is utilized as a research tool for labeling and studying nucleic acids. Its distinct chemical properties allow for the tracking and analysis of RNA structures and functions within biological systems.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 6-Iodouracil serves as a key component in the synthesis of various drugs. Its unique structure contributes to the development of new therapeutic agents with potential applications in treating different diseases.
Used in Organic Compound Preparation:
6-Iodouracil is employed as a precursor in the preparation of a range of organic compounds. Its reactivity and structural features make it a versatile building block for the creation of novel chemical entities.
Used in Cancer Treatment Research:
6-Iodouracil is being investigated for its potential anti-tumor properties. Its therapeutic applications are currently under exploration for the treatment of various types of cancer, offering a promising avenue for future cancer therapies.
Used in Laboratory Settings with Caution:
Due to its mutagenic and genotoxic effects, 6-Iodouracil requires careful handling and use in laboratory settings. Researchers must adhere to safety protocols to minimize potential risks associated with its use.

InChI:InChI=1/C4H3IN2O2/c5-2-1-3(8)7-4(9)6-2/h1H,(H2,6,7,8,9)

Upstream product

• 4270-27-3 6-chlorouracil 

Downstream Products

• 162609-50-9 (E)-6-(3-oxo-3-p-tolylprop-1-enyl)pyrimidine-2,4(1H,3H)-dione 
• 911368-94-0 6-iodo-1,3-bis-(4-methoxy-benzyl)-1H-pyrimidine-2,4-dione 
• 936945-29-8 6-allylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Toward Fractioning of Isomers through Binding-Induced Acceleration of Azobenzene Switching

The E/Z isomerization process of a uracil-azobenzene derivative in which the nucleobase is conjugated to a phenyldiazene tail is studied in view of its ability to form triply H-bonded complexes with a suitably complementary 2,6-diacetylamino-4-pyridine ligand. UV-vis and 1H NMR investigations of the photochemical and thermal isomerization kinetics show that the thermal Z E interconversion is 4-fold accelerated upon formation of the H-bonded complex. DFT calculations show that the formation of triple H-bonds triggers a significant elongation of the NN double bond, caused by an increase of its g? antibonding character. This results in a reduction of the NN torsional barrier and thus in accelerated thermal Z E isomerization. Combined with light-controlled E Z isomerization, this enables controllable fractional tuning of the two configurational isomers.

PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN

Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, L2, and Q are defined herein.

PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN

Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, and Q are defined herein.

Prokineticin 1 receptor antagonists

The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.

PROKINETICIN 2 RECEPTOR ANTAGONISTS

The present invention relates to certain novel compounds of Formula (I): and methods for the treatment of prokineticin 2 or prokinetin 2 receptor mediated disorders.

PYRIMIDINDIONE DERIVATIVES AS PROKINETICIN 2 RECEPTOR ANTAGONISTS

The present invention relates to certain novel compounds of Formula (I), which are suitable for the treatment of prokineticin 2 or prokinetin 2 receptor mediated disorders.